Cargando…
Topical co‐administration of zoledronate with recombinant human bone morphogenetic protein-2 can induce and maintain bone formation in the bone marrow environment
BACKGROUND: Bone morphogenetic proteins (BMPs) induce osteogenesis in various environments. However, when BMPs are used alone in the bone marrow environment, the maintenance of new bone formation is difficult owing to vigorous bone resorption. This is because BMPs stimulate the differentiation of no...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819170/ https://www.ncbi.nlm.nih.gov/pubmed/33472600 http://dx.doi.org/10.1186/s12891-021-03971-w |
_version_ | 1783638959070380032 |
---|---|
author | Ueyama, Hideki Ohta, Yoichi Imai, Yuuki Suzuki, Akinobu Sugama, Ryo Minoda, Yukihide Takaoka, Kunio Nakamura, Hiroaki |
author_facet | Ueyama, Hideki Ohta, Yoichi Imai, Yuuki Suzuki, Akinobu Sugama, Ryo Minoda, Yukihide Takaoka, Kunio Nakamura, Hiroaki |
author_sort | Ueyama, Hideki |
collection | PubMed |
description | BACKGROUND: Bone morphogenetic proteins (BMPs) induce osteogenesis in various environments. However, when BMPs are used alone in the bone marrow environment, the maintenance of new bone formation is difficult owing to vigorous bone resorption. This is because BMPs stimulate the differentiation of not only osteoblast precursor cells but also osteoclast precursor cells. The present study aimed to induce and maintain new bone formation using the topical co-administration of recombinant human BMP-2 (rh-BMP-2) and zoledronate (ZOL) on beta-tricalcium phosphate (β-TCP) composite. METHODS: β-TCP columns were impregnated with both rh-BMP-2 (30 µg) and ZOL (5 µg), rh-BMP-2 alone, or ZOL alone, and implanted into the left femur canal of New Zealand white rabbits (n = 56). The implanted β-TCP columns were harvested and evaluated at 3 and 6 weeks after implantation. These harvested β-TCP columns were evaluated radiologically using plane radiograph, and histologically using haematoxylin/eosin (H&E) and Masson’s trichrome (MT) staining. In addition, micro-computed tomography (CT) was performed for qualitative analysis of bone formation in each group (n = 7). RESULTS: Tissue sections stained with H&E and MT dyes revealed that new bone formation inside the β-TCP composite was significantly greater in those impregnated with both rh-BMP-2 and ZOL than in those from the other experimental groups at 3 and 6 weeks after implantations (p < 0.05). Micro-CT data also demonstrated that the bone volume and the bone mineral density inside the β-TCP columns were significantly greater in those impregnated with both rh-BMP-2 and ZOL than in those from the other experimental groups at 3 and 6 weeks after implantations (p < 0.05). CONCLUSIONS: The topical co-administration of both rh-BMP-2 and ZOL on β-TCP composite promoted and maintained newly formed bone structure in the bone marrow environment. |
format | Online Article Text |
id | pubmed-7819170 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-78191702021-01-22 Topical co‐administration of zoledronate with recombinant human bone morphogenetic protein-2 can induce and maintain bone formation in the bone marrow environment Ueyama, Hideki Ohta, Yoichi Imai, Yuuki Suzuki, Akinobu Sugama, Ryo Minoda, Yukihide Takaoka, Kunio Nakamura, Hiroaki BMC Musculoskelet Disord Research Article BACKGROUND: Bone morphogenetic proteins (BMPs) induce osteogenesis in various environments. However, when BMPs are used alone in the bone marrow environment, the maintenance of new bone formation is difficult owing to vigorous bone resorption. This is because BMPs stimulate the differentiation of not only osteoblast precursor cells but also osteoclast precursor cells. The present study aimed to induce and maintain new bone formation using the topical co-administration of recombinant human BMP-2 (rh-BMP-2) and zoledronate (ZOL) on beta-tricalcium phosphate (β-TCP) composite. METHODS: β-TCP columns were impregnated with both rh-BMP-2 (30 µg) and ZOL (5 µg), rh-BMP-2 alone, or ZOL alone, and implanted into the left femur canal of New Zealand white rabbits (n = 56). The implanted β-TCP columns were harvested and evaluated at 3 and 6 weeks after implantation. These harvested β-TCP columns were evaluated radiologically using plane radiograph, and histologically using haematoxylin/eosin (H&E) and Masson’s trichrome (MT) staining. In addition, micro-computed tomography (CT) was performed for qualitative analysis of bone formation in each group (n = 7). RESULTS: Tissue sections stained with H&E and MT dyes revealed that new bone formation inside the β-TCP composite was significantly greater in those impregnated with both rh-BMP-2 and ZOL than in those from the other experimental groups at 3 and 6 weeks after implantations (p < 0.05). Micro-CT data also demonstrated that the bone volume and the bone mineral density inside the β-TCP columns were significantly greater in those impregnated with both rh-BMP-2 and ZOL than in those from the other experimental groups at 3 and 6 weeks after implantations (p < 0.05). CONCLUSIONS: The topical co-administration of both rh-BMP-2 and ZOL on β-TCP composite promoted and maintained newly formed bone structure in the bone marrow environment. BioMed Central 2021-01-20 /pmc/articles/PMC7819170/ /pubmed/33472600 http://dx.doi.org/10.1186/s12891-021-03971-w Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Ueyama, Hideki Ohta, Yoichi Imai, Yuuki Suzuki, Akinobu Sugama, Ryo Minoda, Yukihide Takaoka, Kunio Nakamura, Hiroaki Topical co‐administration of zoledronate with recombinant human bone morphogenetic protein-2 can induce and maintain bone formation in the bone marrow environment |
title | Topical co‐administration of zoledronate with recombinant human bone morphogenetic protein-2 can induce and maintain bone formation in the bone marrow environment |
title_full | Topical co‐administration of zoledronate with recombinant human bone morphogenetic protein-2 can induce and maintain bone formation in the bone marrow environment |
title_fullStr | Topical co‐administration of zoledronate with recombinant human bone morphogenetic protein-2 can induce and maintain bone formation in the bone marrow environment |
title_full_unstemmed | Topical co‐administration of zoledronate with recombinant human bone morphogenetic protein-2 can induce and maintain bone formation in the bone marrow environment |
title_short | Topical co‐administration of zoledronate with recombinant human bone morphogenetic protein-2 can induce and maintain bone formation in the bone marrow environment |
title_sort | topical co‐administration of zoledronate with recombinant human bone morphogenetic protein-2 can induce and maintain bone formation in the bone marrow environment |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819170/ https://www.ncbi.nlm.nih.gov/pubmed/33472600 http://dx.doi.org/10.1186/s12891-021-03971-w |
work_keys_str_mv | AT ueyamahideki topicalcoadministrationofzoledronatewithrecombinanthumanbonemorphogeneticprotein2caninduceandmaintainboneformationinthebonemarrowenvironment AT ohtayoichi topicalcoadministrationofzoledronatewithrecombinanthumanbonemorphogeneticprotein2caninduceandmaintainboneformationinthebonemarrowenvironment AT imaiyuuki topicalcoadministrationofzoledronatewithrecombinanthumanbonemorphogeneticprotein2caninduceandmaintainboneformationinthebonemarrowenvironment AT suzukiakinobu topicalcoadministrationofzoledronatewithrecombinanthumanbonemorphogeneticprotein2caninduceandmaintainboneformationinthebonemarrowenvironment AT sugamaryo topicalcoadministrationofzoledronatewithrecombinanthumanbonemorphogeneticprotein2caninduceandmaintainboneformationinthebonemarrowenvironment AT minodayukihide topicalcoadministrationofzoledronatewithrecombinanthumanbonemorphogeneticprotein2caninduceandmaintainboneformationinthebonemarrowenvironment AT takaokakunio topicalcoadministrationofzoledronatewithrecombinanthumanbonemorphogeneticprotein2caninduceandmaintainboneformationinthebonemarrowenvironment AT nakamurahiroaki topicalcoadministrationofzoledronatewithrecombinanthumanbonemorphogeneticprotein2caninduceandmaintainboneformationinthebonemarrowenvironment |